商品名:バプレオチド,オクタスタチン,バプレオチド
順序: D-Phe-[Cys-Tyr-D-Trp-Lys-Val-Cys]-Trp-NH2
エイリアス:サンバー,RC-160;バプレオチド;D-PHE-CYS-TYR-D-TRP-LYS-VAL-CYS-TRP-NH2; オクタスタチン;
FCYWKVCW-NH2;D-Phe-L-Cys(1)-L-Tyr-D-Trp-L-Lys-L-Val-L-Cys(1)-L-Trp-NH2;
Cas No.: 103222-11-3
分子式: C57H70N12O9S2
分子量: 1131.40
純度 (HPLC): 98.0%
外観: 白い粉
単一の不純物(HPLC): 1.0%
アミノ酸組成: 10% 理論上の
ペプチド含有量(N%): 80%(%N)
含水量(カール・フィッシャー): 6.0%
アセテート含有量(HPIC): 15.0%
マスバランス: 95.0~105.0%
学年 : 医薬品グレード
保管所: 閉まっている, 下 2 ～8℃保存
使用法 : この薬は、早期の急性食道静脈瘤出血の治療に使用できます (EVB) 止血前の内視鏡的介入療法, 内出血することもあります 5 内視鏡検査後の再発の治療と予防のためのdレンズ。.
Variceal bleeding is a life-threatening complication of portal hypertension. The recommended treatment includes the early administration of a vasoactive drug. Vapreotide is a somatostatin analogue with a different receptor affinity to octreotide. It decreases portal pressure and blood flow of collateral circulation in rats with cirrhosis. The pivotal study of early administration of vapreotide in patients with cirrhosis and variceal bleeding has shown a significant improvement in bleeding control and, in the subset of patients with significant bleeding, a significant reduction in mortality. In addition, a meta-analysis of four randomized studies has shown a significant improvement in bleeding control. Vapreotide administrated via the intravenous route is simple to use, with practically no contraindications and few, usually minor, side effects.
The immediate release formulation of Sanvar, a somatostatin analogue, is used in the treatment of acute esophageal variceal bleeding (EVB).Sanvar is used prior to endoscopic intervention to control haemorrhage and prevent re-bleeding during the critical five days following the onset of bleeding. EVB is a life threatening condition and the mortality rate is high (about 15% に 25%) in the first six weeks following the haemorrhage. EVB is the cause of about 70% of gastro-intestinal bleeding in patients suffering from liver cirrhosis.
